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Abstract
Introduction: Persistent low rates of case notification and treatment coverage reflect that accessing diagnosis and
treatment for drug-resistant tuberculosis (DR-TB) in Nigeria remains a challenge, even though it is provided free of
charge to patients. Equity in health access requires availability of comparable, appropriate services to all, based on
needs, and irrespective of socio-demographic characteristics. Our study aimed to identify the reasons for Nigeria’s low
rates of case-finding and treatment for DR-TB. To achieve this, we analyzed elements that facilitate or hinder equitable
access for different groups of patients within the current health system to support DR-TB management in Nigeria.
Methods: We conducted documentary review of guidelines and workers manuals, as well as 57 qualitative interviews,
including 10 focus group discussions, with a total of 127 participants, in Nigeria. Between August and November 2017,
we interviewed patients who were on treatment, their treatment supporter, and providers in Ogun and Plateau States,
as well as program managers in Benue and Abuja. We adapted and used Levesque’s patient-centered access to care
framework to analyze DR-TB policy documents and interview data.
Results: Thematic analysis revealed inequitable access to DR-TB care for some patient socio-demographic groups.
While patients were mostly treated equally at the facility level, some patients experienced more difficulty accessing
care based on their gender, age, occupation, educational level and religion. Health system factors including positive
provider attitudes and financial support provided to the patients facilitated equity and ease of access. However, limited
coverage and the absence of patients’ access rights protection and considerations in the treatment guidelines and
workers manuals likely hampered access.
Conclusion: In the context of Nigeria’s low case-finding and treatment coverage, applying an equity of access
framework was necessary to highlight gaps in care. Differing social contexts of patients adversely affected their access
to DR-TB care. We identified several strengths in DR-TB care delivery, including the current financial support that should
be sustained. Our findings highlight the need for government’s commitment and continued interventions.
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: omenkac@gmail.com
1The School of Public Health of the University of Montreal (ÉSPUM), 7101,
Parc avenue, 3rd floor, Montreal, Quebec H3N 1X9, Canada
2Centre de recherche en santé publique, Université de Montréal (CReSP),
Montreal, Canada
Full list of author information is available at the end of the article
Oga-Omenka et al. International Journal for Equity in Health          (2020) 19:221 
https://doi.org/10.1186/s12939-020-01342-w
Introduction
Nigeria has overlapping high burdens of tuberculosis (TB),
drug resistant tuberculosis (DR-TB) and HIV, according to
the World Health Organisation (WHO) [1]. However, in
2018, the country of 198 million people had one of the low-
est global TB case detection rates at 15%. Only about 11 and
9% of estimated DR-TB cases were notified and initiated on
treatment, respectively [1]. This highlights major difficulties
in accessing DR-TB care [1]. The country has identified find-
ing the missing TB cases as the single most important prior-
ity for TB control for the upcoming years, as each untreated
case can infect 15–20 persons per year [2].
In terms of health financing, Nigeria spent 3.76% of
gross domestic product (GDP) in 2017 [3]. With a per
capita GDP of USD 5864, 8 and 32% of the TB budget
was domestic and donor funded respectively. This leaves
60% of the National TB budget required to implement
the Stop TB Partnership’s Global Plan to End TB 2018–
2022 unfunded [1, 3, 4]. In addition, 71 % of TB patients
faced catastrophic health costs in 2017 [1].
The healthcare system in Nigeria is provided by the
public healthcare system and an unregulated private sec-
tor [5, 6]. The public system is divided into primary
health centres (PHCs) supported by the local govern-
ment areas, secondary hospitals supported by the State
governments, and tertiary hospitals supported by the
Federal Government [7, 8]. The PHCs were put in place
to serve as the first point of contact with healthcare for
communities, but have been largely abandoned, both by
the local governments and the communities they serve
[7, 8]. Most of the available DR-TB care are in the public
secondary and tertiary hospitals [9].
South Africa and Zimbabwe are two examples of
countries also classified as high burden for TB, DR-TB
and HIV in Africa. In 2017, South Africa spent 8.1% of
its $13,396 GDP (PPP) on health and funded 87% of TB
budget internally, with 0% unfunded. The country had
100 and 87% DR-TB notification and treatment rates in
2018. Comparatively, Zimbabwe spent 6.6% of $2782
GDP (PPP) on health and domestically funded less than
1% of its TB budget; with 31% donor funding, leaving
69% unfunded. Despite this, Zimbabwe had 27 and 25%
DR-TB notification and treatment rates [1, 3, 4]. These
suggest other barriers to TB care in Nigeria, in addition
to health financing.
Equity is fairness or justice [10]. The WHO defines
equity as the absence of avoidable social, economic,
demographic or geographic differences among groups of
people [11]. When applied to healthcare, most defini-
tions of equity include health resources, how these re-
sources are allocated, or align with the needs or
characteristics of populations [10, 12–15]. However,
equity in health care does not always translate to, and
must be differentiated from, equity in health [16, 17].
Integral to these definitions are two key components-
access to healthcare resources and the characteristics of
individuals or populations [10, 13–15, 18].
Equitable health systems ensure services are available
to everyone in need [12, 15, 19–21]. Policy experts have
proposed that governments particularly evaluate health
systems through their impact on the poor, in order to
reverse the inequities in delivery [20, 21]. In the TB con-
text, several authors including the WHO, have
highlighted the need to target specific sociodemographic
groups identified as being at a higher risk of contracting
the disease or of having poorer access or outcomes, once
infected [15, 22, 23]. Another aspect relevant to an
equity analysis is the complexity of the TB care path-
ways- the number of patient visits and pre-treatment
processes needed in order to achieve an outcome.
Access to healthcare is the ability to engage in timely use
of the healthcare services that preserve or improve their
health [18, 24]. Access to healthcare is both opportunity
and ability to obtain needed health services, without risking
financial hardship [25]. It can be defined as the possibility
to identify needs, seek services, reach resources, obtain or
use services, and be offered services appropriate to the
needs of care [14]. Although difficult to measure, equal ac-
cess to healthcare is defined by equal opportunities to ac-
cess and utilize healthcare for those in equal need, resulting
in equitable health outcomes [13, 26]. Using health system
and individual-level data to identify areas of inequity, and
with what factors it is associated, can be a more pragmatic
approach than having a singular overall measure of how
equitable a particular healthcare system is [26].
Equity and ease are two ways of looking at access to
healthcare. Equity of access focuses on the health system, or
supply-side, to ensure equal services for patients in equal
need [27]. Ease of access explores individual and societal bar-
riers to available healthcare services [14, 27]. These individual
or societal barriers to access are inextricably linked to their
social, economic, geographic or demographic characteristics
[13, 14]. Effective and equitable access combines these two
aspects: the ability to obtain timely health services based on
needs, irrespective of sociodemographic characteristics, and
without risking financial hardship [14, 18, 24, 25]. Both are
important access indicators to monitor the performance of
healthcare systems [18, 28, 29]. These definitions are in line
with the Levesque et al. characterisation of access as having
two main domains [14].
This study aimed to explore patient-centered ease and
equity of access to diagnosis and treatment initiation for
DR-TB patients through an analysis of policies, struc-
tures and processes for DR-TB care in Nigeria.
Methodology
We used a transformative study design using key inform-
ant interview, focus group interviews, and document
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review. This is part of a larger mixed methods study, with
previously published quantitative results [30]. In this
paper, we report on the qualitative portion of the data.
We used a transformative design which involves a theoret-
ical lens to guide interpretation and advocate for action
[31, 32]. Transformative research advocates for social just-
ice and addresses power imbalances, by focusing on in-
equalities and marginalization, and this is reflected in
every stage of the research [32, 33]. We focused on under-
standing the perspectives and experiences of patients (in-
cluding those not on treatment), their relatives, care
providers and program managers, through an equity of
healthcare access framework. Our framework, adapted
from the work of several authors [14, 34, 35], helped to
identify inequities within the supply and demand sides of
access, and highlight areas for improvement.
Conceptual framework
The predominant theoretical framework guiding our
transformative study is the Levesque patient-centred ac-
cess to healthcare framework [12, 14, 19]. We chose the
Levesque framework as we identified from our initial lit-
erature review, published elsewhere [36], an interplay of
factors, both between the health system (supply) and pa-
tient (demand) levels, and at different stages of care. The
framework also allowed us to explore some dimensions
of the quality of care (patient-centred, equity, accessibil-
ity) [37, 38], which some authors have called the missing
link in TB care [38, 39], without losing focus on the sup-
ply and demand dynamics of access.
Levesque et al. [14] puts the patients’ needs at the centre
of the healthcare access framework, by focusing on the actual
process of seeking care, including the various stages patients
go through to actually receive needed care, and the abilities
patients need to interact with health services [14]. At its core,
the Levesque framework conceptualizes accessibility in five
dimensions: approachability, acceptability, availability, afford-
ability, and appropriateness. These dimensions must be
matched with five corresponding abilities in patients: ability
to perceive, seek, reach, pay, and engage, respectively [14].
This was also considered through the lens of the con-
tinuum of care in health [34, 40, 41], the TB cascade of
care [34, 42] and the WHO’s health system building
blocks [35]. Our adapted framework (Fig. 1) was used to
frame our qualitative instruments and to interpret
findings.
Fig. 1 An adapted framework of equity and ease of access to DR-TB care
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At its core, the Levesque framework conceptualizes ac-
cessibility in five dimensions: approachability, acceptabil-
ity, availability, affordability, and appropriateness of
providers, organizations, institutions and systems. These
dimensions must be matched with five corresponding
abilities in patients for patients and communities: ability
to perceive (or identify needs), seek services, reach re-
sources, pay, and engage, respectively [14].
These healthcare and patient dimensions should be
progressive as the patient moves from one stage of the
care continuum to the other.
Study population and data collection
We reviewed several National TB and Leprosy Control
Program (NTBLCP) and Federal Ministry of Health
(FMOH) policy and guideline [43–45] documents in-
cluding the workers’ manual [46] and the 2015 annual
TB program report [9], some unpublished program data
[47–49] and WHO country profile [1].
This is part of a larger mixed methods study, with pre-
viously published quantitative results [30] and mixed
methods results [50]. We analysed data from 57 inter-
views. These included focus group discussions (FGDs)
(n = 10) with a total of 81 patients on treatment, treat-
ment supporters and community members; as well as 46
in-depth interviews with untreated patients, healthcare
providers and program managers. Interviews covered 4
locations in Nigeria including Ogun, Plateau, and Benue
states and Abuja, Nigeria, between August and Novem-
ber 2017. Our sampling frame is shown in Fig. 2.
Our overall sampling strategy was purposive [51],
selecting participants whose views would most likely be
information-rich about delays in DR-TB care, as de-
scribed above. Within this sampling approach, we se-
lected participants based on availability and consent.
Healthcare workers’ questions included program struc-
ture, challenges and strengths, as well as their perception
of access barriers and facilitators. Patients and their
treatment supporters were also asked to describe bar-
riers and facilitators to accessing DR-TB care that they,
their relative or someone they knew had experienced.
Female and male only FGDs were additionally probed
for any particular challenges facing their gender in
accessing care. In addition to the questions for health-
care workers, program managers and implementing
partner respondents were asked about the available re-
sources at the national, regional and state level for DR-
TB care, their perspectives on the adequacy of these re-
sources, and relevant policy documents on DR-TB care.
The documents and guides recommended by respon-
dents were also included in the analysis.
Informed consent from each participant were writ-
ten or verbal (where needed), before each interview.
The first author, who had prior DR-TB
implementation experience in Nigeria, carried out the
interviews with help from a field assistant. All inter-
views were conducted in English. However, some
questions were translated into Nigerian pidgin, Yor-
uba or Hausa, if any participant requested it, using
local translators. Interviews were audio-recorded,
translated where needed and transcribed. Where por-
tions of the transcripts included translations and re-
sponses in the other languages, a transcriber fluent in
this language was used. We conducted member
checking as a way to strengthen the rigour of our
study [52]. Transcripts were sent back to all partici-
pants who had earlier agreed to be contacted for ac-
curacy checking, some of whom responded with
revised transcripts which we used to replace the ori-
ginal transcripts.
Data analysis
Data analysis began during data collection to enable ex-
ploration and comparisons of new themes. Our
Qualitative sampling strategy
Fig. 2 Ease and equity of access to free DR-TB care in Nigeria
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interview guide, which was based on our initial literature
review and conceptual framework, was used to deduct-
ively develop a coding tree before the process of coding
began. Transcripts were checked and read through to
give a general understanding of the data. The first phase
of coding was inductive to allow new themes to be
added to the coding tree. Codes were then deductively
matched to the coding tree, with a few new codes added
as needed. Coding of documents and interview tran-
scripts were around themes based on our conceptual
framework of Equity of access to DR-TB care (Fig. 1).
The thematic analysis focused on how the system facili-
tates patient progression after arrival with symptoms at
the TB clinic to the point of treatment initiation, as well
as on patient pathways to care.
Our document analysis, which used content analysis,
helped to triangulate evidence from the in-depth interviews.
This also facilitated member checks (participant feedback
on emerging themes) to ensure fidelity with participant in-
tents as recommended by Seale [53]. Data analysis was fa-
cilitated by the use of the Quirkos software, version 1.6.1.
Our findings are reported according to the consolidated cri-
teria for reporting qualitative studies (COREQ) [54].
Ethics
The National Health Research Ethics Committee of
Nigeria (NHREC/01/01/2007) and the Research Ethics
Committee (CER) of the University of Montreal Hospital
(17.060) granted ethical approval for this study An add-
itional ethical approval was obtained from the Research
Ethics Committee (CER) of sciences and health of the
University of Montreal (CERSES-19-098-D). All partici-
pants gave written or verbal informed consent.
Results
Our findings focus on the outputs needed from the health
system and the patient to achieve DR-TB cure, by looking
at required supply and demand dimensions and how they
align with each step in the care continuum, starting from
symptom recognition, through health-seeking to complet-
ing treatment. The five paired supply and demand dimen-
sions, based on the Levesque framework of patient-
centred healthcare access, is summarised in Fig. 2.
Approachability and ability to perceive
Certain attributes of the healthcare system and of pa-
tients align when the patient recognizes that observed
symptoms require medical attention and that certain
health services can be accessed. The health system en-
ables this through patient education, transparency and
outreach services information. This stage in the care
continuum should end with the patient deciding to seek
care for their health problem.
The national guidelines stressed the need for patient edu-
cation and community awareness and outreach activities.
Routine patient education is to include cause and symptoms
of TB, availability and free cost of treatment, where to seek
healthcare, and how to prevent spread. These activities are to
be implemented through home-based care for HIV and TB
patients. The guidelines encourage healthcare workers to
conduct campaigns and sensitization activities to increase
testing requests, actively search for cases within the health
centers especially for HIV patients, sensitize providers and
engage community-based organizations. However, the guide-
lines are not immediately clear about the frequency or fund-
ing provisions for these campaigns. It also does not say how
active case-finding in the community should be done, al-
though several implementing partners are tasked with these
activities.
Patients, their relatives and providers agreed that there
was limited awareness about DR-TB in the communities.
“The point is, not everybody knows about TB … I
didn’t actually have the full knowledge of what TB
was, so when I got infected, that was when I knew.
Ah, this thing is really serious! But … people out
there, I don’t think the information has been passed
enough to people, especially those in the rural area-
s...they just feel it is this strong cough that doesn’t go
away. [A herbalist] prescribes herbs for [them] to
take and they think okay, it is just a normal cough
that will [go away]....I think the awareness [is im-
portant] because when someone is aware [of] what is
at stake … [they] will be … like... okay, this is [ser-
ious]...lets go to the hospital” (Mixed patients FGD).
This often resulted in prolonged pathways to DR-TB
care, because DR-TB care were most often available in the
public sector. Most of the patients in our focus groups said
they encountered these delays, mostly because of wasted
time in the private sector. These delays ran from 3 months
to 6 months, in a majority of cases, to more than 3 years, in
a few cases, or even death. Patients acknowledged that the
private sector, including patent medicine vendors (PMVs),
community pharmacies and private hospitals, were the first
point of contact with healthcare but that private practi-
tioners had lower index of suspicion for DR-TB, and almost
never referred them to the public sector. This apparent dis-
connection between the private sector and public sector
care, resulting in misdiagnosis and mismanagement, threw
patients into a sometimes-tragic search for a cure.
“So, I [didn’t] really know what to do [anymore] I
was … given the herbal [preparation], I went to
church, I went to mosque, went to everywhere, but
all [remained] the same I won’t lie to you, [DR-TB]
is very strong and very powerful … I [also] went to a
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private hospital for 30 days treatment … they gave
me some drugs to use, but the major [drug] they said
I should be using is rifampicin. I [used] rifampicin
for like two to three years. … When the result [of the
drug susceptibility test] came out, … I was even sur-
prised they wrote rifampicin [resistance] there, and
… it was true I was [ab] using rifampicin” (Diag-
nosed untreated male patient).
“Private hospitals tell [patients] they don’t have
[TB], my younger one that died, we [spent money]
for the ... test, and they still insisted that he did not
have [TB], (Patients FGD)”.
“He was driving [a truck] before, … [so] he stopped
working … I was the one taking care of him at the
Hospital, I [also] stopped my work … He [took herbal
preparations], went to [the] pharmacy to buy medi-
cines for himself, went to every possible place, there
was no cure … He went to prayer houses too. Then
he went to the hospital … the sickness was on and
off. He will recover and fall sick again, that was why
we kept going back … He has been sick for like 6
months [before starting treatment] … The sickness
had already taken over his body, that was why [he
died]”, (Wife of patient who died a few months into
DR-TB treatment).
The Nigerian Annual TB program reports also showed
much lower coverage of free DR-TB services in the pri-
vate sector, limiting the approachability of DR-TB
healthcare.
Respondents mentioned that being told by a health-
care worker in the community, or by a former TB pa-
tient, helped them to realise their symptoms were
treatable for free in the hospital. Healthcare workers
were frustrated that there was more knowledge about
HIV in their communities than of TB.
Government TB control officers and program man-
agers mentioned that outreach activities have increased
case finding in the communities they supervise.
“So, somebody who would have stayed at home using
traditional medicine, thinking that this is just an or-
dinary cough … but with the outreaches, [any] cough
of 2 weeks … please come out for testing, and from
the outreaches a lot of cases have been identified”
(Male program manager).
Acceptability and ability to seek
For a patient to utilize healthcare, the health services
need to have a higher perceived benefit than other op-
tions available to the patient, as well as not to violate
any cultural, religious or social norms the patient has.
This stage is also affected by the health systems profes-
sional values, culture and norms, as well as the patient’s
autonomy. This stage ends with the patient choosing a
particular source or type of care over other options.
As part of the TB private-public partnership strategy,
the TB program worker’s manual included notes to
organize regular meetings with relevant stakeholders in-
cluding PMVs and traditional healers at state levels, with
national oversight. Monitoring meetings with community-
based organizations were also to include religious bodies.
It was not clear from our data how often and where these
activities were happening.
Patients, relatives and providers gave several narratives
of patients visiting multiple sources of alternative care in
search of a cure like PMVs, traditional healers and
prayer houses, and most often before ever going to a
health center. Sometimes, this was due to being unaware
of DR-TB services, inconvenience of these services, mis-
diagnosis in a private hospital or family influence on pa-
tients’ autonomy.
“I have not really seen many [cases like this] …
except for a case of a student I saw when I went
for on a supervisory visit … this student … was
diagnosed with TB but his mum did not believe
that he had TB. His mum felt that it was a spir-
itual issue that should be [handled] with prayers.
I took up the phone and called her and despite
all my pleading and explanation, [and even
though] she said ok she was going to bring her
son the next day, … she never came. … .This is
one clear example of where a parent of a …
minor prevented the child from having access to
care” TB Program Manager Interview.
The documents we reviewed did not mention protect-
ing the right to health for minors, marginalized groups
or other persons who might not be able to take a health
decision on their own.
Other times, it was because the patients had more
confidence in alternative healers than in the public sec-
tor hospital or wrongly attributed TB to other causes. As
one HCW puts it:
“I’ve treated one educated person here, [not] until he
started the drug and [in] the second month [when]
he [could] see the difference that … he believed truly
TB is a disease. [Before then], he believed somebody
[evil was harming] him; [imagine that] an educated
[person]! So I [had] to make copies of … our Na-
tional [training guides], to give to him, to go and
read, that TB is [not supernatural]; and that you
[can] be infected [anywhere], … from an infected
person” HCW interview.
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Patients reported that they preferred to go to private
hospitals because of widespread perception of better
provider attitudes. The major acceptability barriers to
public hospitals included poor provider attitude, unsani-
tary conditions, and lack of essential medical supplies
and accountability.
“Most of private hospital they don’t know [the right
thing to do], and private hospital is where most
people go to. [Government should] first … do some-
thing [about] private hospitals because … people will
think [they] are getting [good treatment], whereas it
is just [the wrong medication] … In this country, if
something happens, people … go to private hospitals,
and they should. [Government hospitals] don’t treat
people well. I can’t give birth in a government hos-
pital , my younger one was dying in a government
hospital and they said it is not their business, if you
don’t get a particular [item], if you don’t get [say, a
facemask], they will not attend to [your] child, before
we could get [the facemask], the child had died. Gov-
ernment hospitals treat people like dogs, like ani-
mals, like … whatever happens to you is not their
business, they will [still] get paid. In private hospi-
tals, they will be sweeping and cleaning every minute
… , and telling you sorry every time, [and] you … feel
a little bit consoled” (Female patients FGD 1).
Patients were more inclined to use the public sector
on the recommendation of someone in their community
that they trusted, like their pastor or family member. In-
terviews with members of the community also
highlighted the effect of community awareness cam-
paigns in changing people’s beliefs about health services.
Availability, accommodation and ability to reach
For patients to be able to reach a health service, it needs
to be geographically available, with accessible opening
hours and appointment systems. The patient should
have access to secure transport to reach these services.
At the health facility, the patient needs to come in con-
tact with a knowledgeable provider who suspects and
tests for DR-TB. This would also need to align with the
patient’s support system. At the end of this cascade
stage, the patient should be known to the health system
and recorded as “tested”.
Based on the annual National TB program reports and
data from 2015 to 2017 that were part of our document
review, coverage in services was scaled up nationally:
testing facilities increased from 201 to 386 (testing), in-
patient treatment centres from 13 to 29 and community
outpatient treatment centres from 5 to 200. Most of the
testing facilities were located in the tertiary and second-
ary public health centres, with only13 and 6% of testing
in the private sector and primary health care level re-
spectively. In-patient treatment centres were in 27 out of
37 states, and all were in tertiary or secondary facilities,
with 17% in private hospitals, excluding patients who
were initiated on treatment in the communities. Geo-
graphic coverage of testing was 48% at the end of 2017.
Respondents mentioned the lack of testing and treat-
ment facilities near them as a barrier. Many patients
lived far from the health facility, with transportation dif-
ficulties, especially in rural areas.
“Some people do not have the opportunity to come
down to this place; if it is in their State they will also
be able to go to the clinic close to them to [test],
knowing that when they get there they will [be
treated] well” (Female patients FGD 1).
Several health system barriers were noted including
clinic and laboratory operational delays, data errors and
stock-outs of essential health products. Healthcare
workers gave instances of patients giving wrong contact
information, due to poor confidence in the public
healthcare system, which affected patient tracking and
resulted in loss to follow-up. The treatment guidelines
and workers manuals we looked at did not include any
procedure for address verification for patients being
tested or initiated on treatment.
Healthcare workers also noted limited staff numbers
as a major challenge.
“... because we don’t have manpower on ground. …
In a particular facility probably, they are only two
[staff] and in some cases there is only one personnel.
Now you will be handling this, … you will be doing
this [and that]. So, at the end you may not even
have time for some of your patients ... that is the
greatest challenge we have” (Female HCW)
Affordability and ability to pay
The direct and indirect costs of accessing care and the
patient’s socioeconomic situation determine whether a
patient gets diagnosed and placed on treatment. These
costs and ability to keep paying for them will determine
if the patient initiates and continues on treatment.
Patients narrated facing catastrophic treatment costs,
mostly in the private sector, before finding the right
health center for DR-TB care. Other direct and indirect
costs were related to transportation for follow-up ap-
pointments and for pre-treatment investigations.
However, with support from partners, the TB program
pays transport and social support to patients enrolled on
treatment, at approximately USD100 per month [48].
Patients and their relatives repeatedly mentioned that
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the financial support was the biggest facilitator of access
for them.
“We thank the sponsors of [this] program because if
not for them, things would have gone wrong. Because
so many [people] didn’t go for [the] injections be-
cause of money, so many [people didn’t] have money
for [transportation], feeding but we thank [the pro-
gram]. If not for the money [they] gave us, many
[more] would have died. Things would have gone
[very] wrong [for us] but we thank them …. Thank
you very much.” (Treatment supporters FGD).
“I used to hear that they heal people with [TB here],
but I was like - how much will I [need to pay when I
get here]; but when I heard it was free, that was
what gave me the opportunity to come here” (Fe-
male-only FGD).
Appropriateness and ability to engage
The healthcare system also needs to be efficacious, well-
coordinated, uninterrupted and support the patient to
be empowered and adhere to the treatment regimen to
its completion. The patient also needs to be able to tol-
erate or withstand the effects of treatment and have ad-
equate support from their social network. Only then can
the desired treatment outcome be achieved.
There were instances of patients losing hope during
the long duration of treatment or having unbearable side
effects, including pain from injections, to the point
where the possibility of dying was preferable to
remaining on treatment.
“[An elderly man], … when he sees the tray for drugs,
… he will start vomiting, ha! even when they have
not given him, as soon as he sees it, he starts vomit-
ing. At last even nurse or doctor, when he sees them
he will just start vomiting, and finally he said he
wants to go, … if he even sees the color of the doctors
or nurses uniform he will be so afraid … he said it is
better for him to go and die … maybe he is dead but
we don’t know, but if he just sees them even there is
no drugs he will start vomiting. .. they gave him
paper to sign out of treatment … and he signed out
and left because he [couldn’t] bear the pain [any-
more]” (Female patients FGD 2).
“I lost hope...It got to a point, I was throwing my
drugs away, because I just told them they should
leave me to [die]... I was just so tired of everything”
Patients FGD.
“We have some that after starting treatment, due to
adverse drug reaction you know, some of them may
tell you that I better die than to be taking this drug”
HCW interview.
In several cases, having a caring healthcare worker made
the difference between continuing treatment or not.
“Taking the drugs, to be frank, is very difficult.
When you take the drugs, you will feel serious
pain. Sometimes some people will be shouting,
shouting; … the injection is like that. … sometimes
we are together with the nurses while the injection
is being given, and during that period, you will be
see different people shouting, shouting because of
the injection, some people will even be running
from the injection. To be frank the nurses are very
caring. and God will bless them all for their ef-
fort” Female Patients FGD.
“After some months, I saw the next [medication], I
refused because the pain [I was] going through. So, I
didn’t want to take the treatment, but the way [the
HCWs] talked, pleaded. When they came, they
started pleading with me … That’s why I … decided,
let [me just] go ahead and take it” Mixed Patients
FGD.
Healthcare workers cited a few instances of patients
whose families prevented their treatment completion be-
cause of their own beliefs that the private sector will
offer a cure.
At the health system level, several barriers were noted,
including stock out of essential supplies, and inadequate
patient counseling.
Overview of equity and ease of access to free DR-TB
services
Our document review found, and providers and the pa-
tients affirmed that the DR-TB program provided finan-
cial support for patients on treatment, which patients
acknowledged as the main facilitator to access.
“The day they gave me the result and said it was
TB, I was like ah! And I started thinking that
where do I … get money [for treatment]. I told my
husband and he was worried. The doctor then
said that whatever we are using here will be free
of charge. I was like, it a lie, there is no [way] I
will come here and will not spend money. I
wanted to drop the money on me. They were like,
no, I should go [home] with it.... When we got to
where we will do [the] X-ray, I [asked], how much
am I spending? They said I am not spending any-
thing, that I should go home, because everything
they do here is free.” Patients FGD.
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There were very many instances of healthcare workers
personally going above the line of duty to help patients
remain in care.
“We pay nothing. Even when I go to hospital without
money, the person giving us drug [would] give me
money for transport from her personal purse and I
keep thanking her till today because she really took
good care of me” Patients FGD.
However, to be placed on treatment, there were sig-
nificant challenges with coverage of services, prolonged
care processes, operational errors and provider attitudes.
“When I got to that general hospital to do test … ,
which [was 6 months ago] they said … am going to
do eight tests, am going to do seven there [at the gen-
eral hospital] then the other one at [another loca-
tion]. [eventually], I did everything, I have [done] the
… seventh test at general [hospital] … so it is
remaining, one, at [the other location], they said that
one … audiometric or (hiss) I have forgotten what
the doctor called it. … which is the eight one. … [I
just did], the x-ray. Everything -the results- are still
at home” (Untreated male patient).
All groups of respondents mentioned that some
groups of patients had more difficulty accessing care.
These include patients living in rural communities far
from TB healthcare centres, children whose parents
had low trust or information about public healthcare,
patients in the private sector, women due to adverse
cultural norms that necessitated asking for their hus-
bands’ permission to access care, workers and
students.
These difficulties are reflected in the following quotes:
“A 12 years old [girl] came down with … resistance
and the mother vehemently refuse to take her for
treatment all in the name of she has given her some
cough syrup. The state team went there … yet this
woman stood her ground that she will not allow the
daughter to leave … The TBLS (TB Local Govern-
ment Supervisor) … the woman took one knife at …
him … So, now the small [child] that is bearing the
pain. But because she is small, she can’t take deci-
sion on her own.” (Male program manager).
Livelihoods and education were threatened or inter-
rupted, even for patients’ relatives, in order to navigate
the process of care.
“I was learning before, I should have finished learn-
ing this year before this TB stopped my learning. It
was remaining 4 months for me to complete” (Fe-
male patient relative).
“The reason why I don’t want to start now is that …
is work! My work … And my house rent is going to
be due in November which is next two months; …
the reason why I don’t want to [go for treatment]
now, is that if the house rent should be due [how
can] I tell my landlord that I am leaving for the hos-
pital?! ...I am going to pay for the house rent” (Un-
treated male patient).
Overall, there was cohesiveness between data source
(document versus interviews) and respondent type.
However, there were a couple of differences. For ex-
ample, while the national guidelines recommended that
community awareness be carried out, it was not very
clear how these were to be funded or implemented by
the healthcare worker. Also, several healthcare workers
cited cases of female patients and children being pre-
vented from accessing care because of an authority fig-
ure, participants in the female-only FGDs did not
mention this, even when probed specifically for this.
However, a phone interview with a female adult patient
living with her father, was interrupted by the father, who
asked that his daughter never be contacted again by the
DR-TB program as she was already healed by prayers.
Discussion
We conducted qualitative interviews in 4 Nigerian states,
combining this with documentary review of guidelines
and policies in place within the DR-TB program, in
order to explore barriers to access along the pathway to
care. Our findings highlight gaps in equity of access to
DR-TB healthcare, in terms of approachability, accept-
ability, availability, affordability and appropriateness.
Overall, our results agree with most of the findings from
other sub-Saharan African countries, detailed in our pre-
viously published systematic review [36].
Our study identified several barriers within the current
DR-TB health system that impede equitable access along
the pathway to care for different groups of patients. We
identified access to information about TB in general,
and about the availability of free services in particular, as
a major challenge, preventing engagement with the sys-
tem and leading to prolonged care pathways. A study in
Nigeria on health-seeking pathways of TB patients found
that the perceived cause of TB influenced their first
choice of treatment [55]. Patients who believed TB was
caused by witchcraft were more likely to use alternative
treatments. Many participants in our study observed that
patients only go the hospital after exhausting other op-
tions in the private sector. Treatment delays were, thus,
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related more to inadequate community awareness about
TB disease and available services, and distrust of the
public sector, agreeing with several studies in sub-
Saharan Africa [56–58]. Approachability in several SSA
countries were hampered by poor provider knowledge
and attitudes, poor referral systems and patient tracking,
as in our study [57–68].
The lack of referrals between the private and public sec-
tor in our study has been found in other studies [59–61].
This was identified as a major missed opportunity for DR-
TB care, as the private sector remains the first point of
healthcare contact for many TB patients [5].
Poor approachability and ability to perceive often re-
sulted in patients not being accepting of available ser-
vices, preferring alternatives. This has been highlighted
in other SSA studies [56, 57, 69, 70].
Inadequate coverage of diagnostic and treatment facil-
ities, as well as the poor availability of health products
and other operational challenges is well documented in
studies from SSA [56–58, 62, 65–68, 70–79]. Our study
agrees with these findings.
A number of studies have identified the indirect costs of
care including paying for transport to health facilities, and
other high opportunity costs borne by patients [57, 68].
Participants in our study mentioned repeatedly mentioned
these costs, which were alleviated by the financial support
provided by the program.
Our study also identified barriers to access that are
not so common in literature – where family members
impeded patients’ care, particularly women and children,
due to their own distrust in the health system or prefer-
ence for alternative care.
As a limitation, we were not able to corroborate that
all the documents reviewed were sufficiently available to
field staff, and how much these documents influenced
their practice, and it might be necessary to evaluate this
effect in future research. The major documents with
which most of the healthcare workers were familiar were
the TB guidelines and workers’ manuals. Secondly, the
purposive sampling method we used may have intro-
duced selection bias.
Another limitation is the fact that some of our tran-
scripts included responses in other languages that had to
be translated. We were not always able to receive feed-
back from these respondents on the accuracy of our
translations.
Recommendations
In line with our transformative research approach [32,
33], we emphasize possible interventions to enhance
ease and equity of access, based on our findings. In order
to improve case finding and treatment coverage rates,
the TB program in Nigeria needs to focus attention at
the different contextual and health system factors im-
peding access.
Several community health awareness interventions
across different disease settings have documented ef-
fectiveness, and these include ‘edutainment’ using
media (radio, TV and print), school and community
outreaches, dedicated community helplines in local
languages [80–86]. These messages need to be tai-
lored to context and culturally sensitive to be effect-
ive and will go beyond the current strategies
employed by the Nigerian TB program, which include
patient educational posters on the walls of facilities
and periodic active case finding in communities. The
current strategies rely on a TB patient presenting vol-
untarily at a facility before learning about available
services, or through targeted active case finding activ-
ities by implementing partners.
Another opportunity for improving equity of access is
improving the referral system between the private and
public sectors. Nigeria has one of the highest percentage
of patients using the private sector as first point of care
(66–92%) in the world, with the over 60,000 PMVs in
the country [5]. Currently, the TB program has mecha-
nisms in place to meet with representatives from
community-based organizations, including traditional and re-
ligious organizations, and there are implementing partners
working on improving private sector engagement [5]. How-
ever, these efforts have not translated to significant improve-
ments in referral between the private and public sector [5].
Current fees-for-referrals from private facilities will need sus-
tained funding, and additional research is needed to find out
more about these programs, including coverage and whether
information about the scheme is available to all PMVs and
private hospitals. As suggested by the respondents them-
selves, we agree that media engagement is an opportunity to
increase public awareness using culturally adapted media
programs in different languages to take the information dir-
ectly into communities where it is most needed.
An immediate step for the National program could in-
clude additional address verification for all patients being
tested for TB. The TB and DR-TB guidelines currently do
not include instructions to public providers on address
verification steps, unlike in the South African and Zim-
babwean guidelines [87, 88]. Verifying contact informa-
tion, especially in settings with informal address systems,
has potential in reducing loss to follow-up and improving
contact tracing [89–91]. One possibility might for the TB
program to ask patients to provide contact verifiable ad-
dresses for their treatment supporters on testing to serve
as an additional way to contact patients if they become
lost to follow-up; this ‘guarantors’ or ‘referees’ system has
been used successfully by financial institutions in Nigeria
and similar settings to recover bad loans [92–95]. How-
ever, operational issues will need to be monitored and
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addressed to ensure that the benefits outweigh the costs
of this additional task in an already overburdened system.
Compared to guidelines from South Africa and
Zimbabwe [87, 88], the guideline from Nigeria would
benefit from the inclusion of clearly delineated timelines
such as replacing “early diagnosis” with “diagnosis of DR-
TB within 48 hours of submitting a sample” and “timely
treatment initiation” with “commencement of TB treat-
ment within five days of reporting to a health facility with
symptoms of TB”. The Nigerian guideline could also
benefit from the inclusion of relevant sections from the
Nigerian Health Act that give weight to patient’s rights or
highlight penalties for endangering the health of others by
refusing care or preventing them from accessing care. This
would protect the rights of women and children identified
in our study as having limited autonomy to access care.
In our literature review published earlier, we sum-
marised recommendations made by the authors to im-
prove the barriers to access by paired dimensions [36].
Conclusions
DR-TB services in Nigeria are not always equitable, and
patients face significant barriers to care. Our findings
highlight health system barriers around coverage, opera-
tions errors, and provider attitudes, with patient finan-
cial support as a major facilitator; and patient barriers of
awareness, perceptions of poor public sector care, beliefs
and preference for alternative care. We discussed several
opportunities for improvement to the demand and sup-
ply factors impacting access to DR-TB healthcare. Given
the urgent need to increase notification and treatment
coverage, there is a need for the TB program to innovate
and reduce these barriers as well as adapting to the
needs of the patients, including improving referral sys-
tem with the private sector, community awareness, and
protecting the rights of patients with limited autonomy.
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